---
title: "Stelara (ustekinumab) in plaque psoriasis: Safety questions"
description: "Safety questions on Stelara (ustekinumab) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects, Warnings, and Safety evidence. Questions: Do patients develop antibodies to Stelara in plaque psoriasis (immunogenicity)? What are the most common side effects of Stelara for plaque psoriasis? Which Stelara side effects were more common than placebo in psoriasis trials? Does Stelara increase the risk of serious infections? 4 further questions follow. 8 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/safety"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Stelara (ustekinumab) in plaque psoriasis: Safety questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Stelara](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf)

Safety questions that apply to every indication of Stelara are on [Stelara (ustekinumab), all indications: Safety](https://www.evicenter.com/medical-information/stelara/safety).

## Side effects

<a id="stelara-antibodies"></a>

### Do patients develop antibodies to Stelara in plaque psoriasis (immunogenicity)?

Applies to: Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

> “The observed incidence of anti-drug antibodies is highly dependent on the 
> sensitivity and specificity of the assay. Differences in assay methods preclude 
> meaningful comparisons of the incidence of anti-drug antibodies in the studies 
> described below with the incidence of anti-drug antibodies in other studies, 
> including those of ustekinumab or other ustekinumab products.”

Source: [STELARA: Prescribing information, page 8, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=8)

> “Approximately 6 to 12.4% of subjects treated with STELARA in clinical trials in 
> subjects with plaque psoriasis and psoriatic arthritis developed antibodies to 
> ustekinumab, which were generally low-titer. In clinical trials in subjects with 
> plaque psoriasis, antibodies to ustekinumab were associated with reduced or 
> undetectable serum ustekinumab concentrations and reduced efficacy. In trials 
> in subjects with plaque psoriasis, the majority of subjects who were positive for 
> antibodies to ustekinumab had neutralizing antibodies.”

Source: [STELARA: Prescribing information, page 8, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=8)

Note: The 6 to 12.4% range pools the plaque psoriasis and psoriatic arthritis trials; the label gives no separate range for plaque psoriasis.

<a id="stelara-side-effects"></a>

### What are the most common side effects of Stelara for plaque psoriasis?

> “The most common adverse reactions (≥3% and higher than that with placebo) in adults from plaque psoriasis clinical trials for STELARA 45 mg, STELARA 90 mg, or placebo were: nasopharyngitis (8%, 7%, 8%), upper respiratory tract infection (5%, 4%, 5%), headache (5%, 5%, 3%), and fatigue (3%, 3%, 2%), respectively. The safety profile in pediatric patients with plaque psoriasis was similar to that of adults with plaque psoriasis.”

Source: [STELARA: Important Safety Information, captured 2026-11-13](https://www.stelarahcp.com/plaque-psoriasis/important-safety-information/#:~:text=The%20most%20common%20adverse%20reactions,of%20adults%20with%20plaque%20psoriasis.)

<a id="stelara-side-effects-table"></a>

### Which Stelara side effects were more common than placebo in psoriasis trials?

Applies to: Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

> “Table 9: Adverse Reactions, Reported by ≥1% of Subjects with Plaque Psoriasis 
> and at Higher Rates in the STELARA Groups through Week 12 in Ps 
> STUDY 1 and Ps STUDY 2
> STELARA
> Placebo
> 45 mg
> 90 mg
> Subjects treated
> 665
> 664
> 666
> Nasopharyngitis
> 51 (8%)
> 56 (8%)
> 49 (7%)
> Upper respiratory tract infection
> 30 (5%)
> 36 (5%)
> 28 (4%)
> Headache
> 23 (3%)
> 33 (5%)
> 32 (5%)
> Fatigue
> 14 (2%)
> 18 (3%)
> 17 (3%)
> Back pain
> 8 (1%)
> 9 (1%)
> 14 (2%)
> Dizziness
> 8 (1%)
> 8 (1%)
> 14 (2%)
> Pharyngolaryngeal pain
> 7 (1%)
> 9 (1%)
> 12 (2%)
> Pruritus
> 9 (1%)
> 10 (2%)
> 9 (1%)
> Injection site erythema
> 3 (<1%)
> 6 (1%)
> 13 (2%)
> Myalgia
> 4 (1%)
> 7 (1%)
> 8 (1%)
> Depression
> 3 (<1%)
> 8 (1%)
> 4 (1%)”

Source: [STELARA: Prescribing information, page 4, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=4)

> “Adverse reactions that occurred at rates less than 1% in the controlled period of 
> Ps STUDIES 1 and 2 through week 12 included: cellulitis, herpes zoster, 
> diverticulitis, and certain injection site reactions (pain, swelling, pruritus, 
> induration, hemorrhage, bruising, and irritation).”

Source: [STELARA: Prescribing information, page 5, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=5)

Note: Table 9 columns are placebo, STELARA 45 mg, and STELARA 90 mg; the header row places STELARA above the 45 mg and 90 mg columns.

## Warnings

<a id="stelara-infection-risk"></a>

### Does Stelara increase the risk of serious infections?

> “STELARA may increase the risk of infections and reactivation of latent infections. 
> Serious bacterial, mycobacterial, fungal, and viral infections were observed in 
> patients receiving STELARA [see Adverse Reactions (6.1, 6.2)].”

Source: [STELARA: Prescribing information, page 4, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=4)

> “Serious infections requiring hospitalization, or otherwise clinically significant 
> infections, reported in clinical trials included the following: 
> •	 Plaque Psoriasis: diverticulitis, cellulitis, pneumonia, appendicitis, cholecystitis, 
> sepsis, osteomyelitis, viral infections, gastroenteritis, and urinary tract infections.”

Source: [STELARA: Prescribing information, page 4, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=4)

> “Avoid initiating treatment with STELARA in patients with any clinically important 
> active infection until the infection resolves or is adequately treated. Consider the 
> risks and benefits of treatment prior to initiating use of STELARA in patients with 
> a chronic infection or a history of recurrent infection.”

Source: [STELARA: Prescribing information, page 4, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=4)

> “Instruct patients to seek medical advice if signs or symptoms suggestive of an 
> infection occur while on treatment with STELARA and discontinue STELARA 
> for serious or clinically significant infections until the infection resolves or is 
> adequately treated.”

Source: [STELARA: Prescribing information, page 4, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=4)

<a id="stelara-cancer-risk"></a>

### Does Stelara increase the risk of cancer?

> “STELARA is an immunosuppressant and may increase the risk of malignancy. 
> Malignancies were reported among subjects who received STELARA in clinical 
> trials [see Adverse Reactions (6.1)]. In rodent models, inhibition of IL-12/IL-23p40 
> increased the risk of malignancy [see Nonclinical Toxicology (13.1)].
> The safety of STELARA has not been evaluated in patients who have a history of 
> malignancy or who have a known malignancy.
> There have been post-marketing reports of the rapid appearance of multiple 
> cutaneous squamous cell carcinomas in patients receiving STELARA who had 
> pre-existing risk factors for developing non-melanoma skin cancer. Monitor all 
> patients receiving STELARA for the appearance of non-melanoma skin cancer. 
> Closely follow patients greater than 60 years of age, those with a medical history of 
> prolonged immunosuppressant therapy and those with a history of PUVA treatment 
> [see Adverse Reactions (6.1)].”

Source: [STELARA: Prescribing information, page 4, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=4)

> “The most frequently observed malignancies other than NMSC during the clinical trials were prostate, melanoma, colorectal, and breast
>
> Malignancies other than NMSC in STELARA<sup>®</sup>-treated patients during the controlled and noncontrolled portions of studies were similar in type and number to what would be expected in the general US population according to the Surveillance, Epidemiology, and End Results (SEER) database (adjusted for age, gender, and race). <sup>2,3 †</sup>”

Source: [STELARA: STELARA® (ustekinumab) Safety Profile: Plaque Psoriasis, captured 2026-11-13](https://www.stelarahcp.com/plaque-psoriasis/safety-profile/#:~:text=The%20most%20frequently%20observed%20malignancies,for%20age%2C%20gender%2C%20and%20race%29.)

> “†SEER database (2009), adjusted for age, gender, and race, compared with STELARA <sup>®</sup> through the 2011 analysis.<sup>3</sup>”

Source: [STELARA: STELARA® (ustekinumab) Safety Profile: Plaque Psoriasis, captured 2026-11-13](https://www.stelarahcp.com/plaque-psoriasis/safety-profile/#:~:text=%E2%80%A0SEER%20database%20%282009%29%2C%20adjusted%20for,through%20the%202011)

<a id="stelara-tb-test"></a>

### Do patients need a TB test before starting Stelara?

> “Evaluate patients for tuberculosis infection prior to initiating treatment 
> with STELARA.
> Avoid administering STELARA to patients with active tuberculosis infection. Initiate 
> treatment of latent tuberculosis prior to administering STELARA. Consider anti-
> tuberculosis therapy prior to initiation of STELARA in patients with a past history of 
> latent or active tuberculosis in whom an adequate course of treatment cannot be 
> confirmed. Closely monitor patients receiving STELARA for signs and symptoms of 
> active tuberculosis during and after treatment.”

Source: [STELARA: Prescribing information, page 4, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=4)

## Safety evidence

<a id="stelara-infection-rates"></a>

### How often did infections occur with Stelara in psoriasis trials?

Applies to: Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

> “In the placebo-controlled period of clinical studies of patients with psoriasis (average follow-up of 12.6 weeks for placebo-treated patients and 13.4 weeks for STELARA <sup>®</sup>-treated patients)<sup>2</sup>:
>
> 27% of STELARA<sup>®</sup>-treated patients reported infections (1.39 per patient-year of follow-up) compared with 24% of placebo-treated patients (1.21 per patient-year of follow-up)
>
> Serious infections occurred in 0.3% of STELARA<sup>®</sup>-treated patients (0.01 per patient-year of follow-up) and in 0.4% of placebo-treated patients (0.02 per patient-year of follow-up)”

Source: [STELARA: STELARA® (ustekinumab) Safety Profile: Plaque Psoriasis, captured 2026-11-13](https://www.stelarahcp.com/plaque-psoriasis/safety-profile/#:~:text=In%20the%20placebo%2Dcontrolled%20period%20of,%280.02%20per%20patient%2Dyear%20of%20follow%2Dup%29)

<a id="stelara-long-term-side-effects"></a>

### What are the long-term side effects of Stelara for psoriasis?

Applies to: Adults with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

> “The safety data reflect exposure to STELARA<sup>®</sup> in 3117 adult psoriasis subjects, including 2414 exposed for at least 6 months, 1855 exposed for at least 1 year, 1653 exposed for at least 2 years, 1569 exposed for at least 3 years, 1482 exposed for at least 4 years and 838 exposed for at least 5 years.<sup>2</sup>”

Source: [STELARA: STELARA® (ustekinumab) Safety Profile: Plaque Psoriasis, captured 2026-11-13](https://www.stelarahcp.com/plaque-psoriasis/safety-profile/#:~:text=The%20safety%20data%20reflect%20exposure,exposed%20for%20at%20least%205)

> “In the controlled and noncontrolled portions of psoriasis clinical trials (median follow-up of 3.2 years, representing 8998 patient-years of exposure)<sup>2</sup>:
>
> 72.3% of STELARA<sup>®</sup>-treated patients reported infections (0.87 per patient-year of follow-up)*
>
> Serious infections were reported in 2.8% of patients (0.01 per patient-year of follow-up)
>
> 1.7% of STELARA<sup>®</sup>-treated patients reported malignancies excluding nonmelanoma skin cancers (NMSC) (0.60 per hundred patient-years of follow-up)
>
> NMSC was reported in 1.5% of STELARA<sup>®</sup>-treated patients (0.52 per hundred patient-years of follow-up)”

Source: [STELARA: STELARA® (ustekinumab) Safety Profile: Plaque Psoriasis, captured 2026-11-13](https://www.stelarahcp.com/plaque-psoriasis/safety-profile/#:~:text=In%20the%20controlled%20and%20noncontrolled,%280.52%20per%20hundred%20patient%2Dyears%20of%20follow%2Dup%29)

> “Cumulative overall safety was evaluated during the placebo-controlled period (12 or 20 weeks) and up to 5 years of treatment.<sup>3</sup>”

Source: [STELARA: STELARA® (ustekinumab) Safety Profile: Plaque Psoriasis, captured 2026-11-13](https://www.stelarahcp.com/plaque-psoriasis/safety-profile/#:~:text=Cumulative%20overall%20safety%20was%20evaluated,up%20to%205%20years%20of)

> “*Based on any adverse event, regardless of body system, which in the opinion of the investigator would be considered an infection.”

Source: [STELARA: STELARA® (ustekinumab) Safety Profile: Plaque Psoriasis, captured 2026-11-13](https://www.stelarahcp.com/plaque-psoriasis/safety-profile/#:~:text=%2ABased%20on%20any%20adverse%20event%2C,would%20be%20considered%20an%20infection.)

## Related pages
- [Medical information: Stelara (ustekinumab): Plaque psoriasis](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/clinical-trials)
- [Real-world evidence](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/real-world-evidence)
- [Specific populations](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis/storage-and-supply)
